3 results
Approved WMOCompleted
Primary objective:Evaluate the effect of two doses versus placebo gantenerumab subcutaneous injections on the change in Clinical Dementia Rating Sum of Boxes scale (CDR SOB), a global measure of cognition and functional capacitySecondary objectives:…
Not approvedWill not start
The primary objective of this secondary prevention study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of gantenerumab, an anti-amyloid antibody, in amyloid-positive, cognitively unimpaired participants at risk for or…
Approved WMOCompleted
This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early (prodromal to mild) Alzheimer's disease (AD).